AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

Trial Details

NCT ID
NCT05602363
Phase
PHASE1
Sponsor
Carna Biosciences, Inc.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Docirbrutinib
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311
  • Miami Beach, Florida, United States|25.79065,-80.13005
  • Tampa, Florida, United States|27.94752,-82.45843
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Fort Wayne, Indiana, United States|41.1306,-85.12886

Key Eligibility Criteria

  • Age ≥18 years
  • Provided written informed consent
  • Histologically confirmed B-cell malignancy, including CLL/SLL, WM, MCL, MZL, or FL
  • Patients with SLL, MCL, MZL, and FL: at least 1 radiographically measurable lesion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →